

Attorney Docket No. SURR.113

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

**ALLISON** 

SERIAL NO.:

10/632,694

10/032,094

ART UNIT:

FILED:

AUGUST 1, 2003

}

1653

EXAMINER: SNEDDEN, S.

**CONFIRMATION NO.: 3876** 

TITLE:

MODIFIED ANNEXIN PROTEINS AND METHODS FOR TREATING VASO-OCCLUSIVE SICKLE-CELL

DISEASE

Mail Stop: Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

## TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(d). This Statement is filed after a final action under 37 CFR § 1.113, after a notice of allowance under 37 CFR § 1.311, or after an action that otherwise closes prosecution on the merits, but <u>before</u> or simultaneously with the payment of the issue fee.

## Certification under 37 CFR § 1.97(e)(2)

The undersigned hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Submitted herewith is a check in the amount of \$180.00 in accordance with 37 CFR

37 CFR 1.8 CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

Mail Stop: Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

Signature:

a L. Pierce

11/22/2004 JBALINAN 00000018 10632694

180.00 OP

01 FC:1806

§ 1.17(p). It is believed that no other fees are due with this submission. If this is in error, please charge Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: November 16, 2001

Darla G. Yoerg, #48,053

Swanson & Bratschun, L.L.C.

1745 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129

Telephone:


(303) 268-0066

Facsimile:

(303) 268-0065

cc: W. Leschensky

S:\CLIENTFOLDERS\SURROMED\113\IDS03.DOC



ATTY. DOCKET NO.	SERIAL NO.	
SURR.113	10632694	
APPLICANT		
ALLISON		
FILING DATE	GROUP	
8/1/03	1653	

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	6323313	11/27/01	TAIT ET AL.			
	AB	5955437	9/21/99	REUTELINGSPERGER			
	AC	5484711	1/16/96	WALLNER ET AL.			
	AD	20040002056	1/1/04	LORENS ET AL.			
	AE						
	AF						
	AG						
	АН						
	AI						
	AJ						

			FOREIGN PATEN	r documents	* 4		
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRAN S?
	AK						
	AL			5.000			
	AM						
	AN						
	AO						

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AP	VAN HEERDE (1994) ARTERIOSCLER THROMB 14-824
AQ	ROMISCH ET AL. (1991) THROMBOSIS RESEARCH 61:93-104
AR	
AS	
AT	
AU	
AV	
AW	
AX	
AY	
AZ	
EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.